Comparative Pharmacology
Head-to-head clinical analysis: LEVOXYL versus TRIALODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOXYL versus TRIALODINE.
LEVOXYL vs TRIALODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levothyroxine is a synthetic thyroid hormone (T4) that is deiodinated to triiodothyronine (T3) in peripheral tissues, binding to thyroid hormone receptors in the nucleus and increasing metabolic rate, protein synthesis, and oxygen consumption.
TRIALODINE is a selective serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that potentiates the effects of serotonin, norepinephrine, and dopamine by blocking their reuptake at presynaptic neurons.
Initial adult dose: 25-50 mcg orally once daily; titrate by 12.5-25 mcg every 6-8 weeks based on TSH. Maintenance dose: 50-200 mcg orally once daily.
50–100 mg orally twice daily; maximum 200 mg/day.
None Documented
None Documented
6-7 days in euthyroid patients; prolonged in hypothyroidism (9-10 days), shortened in hyperthyroidism (3-4 days); clinical steady-state after 6-8 weeks of consistent dosing.
Terminal elimination half-life is 6-8 hours in healthy adults; prolongs to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal (30-50% as unchanged drug and conjugates); fecal (biliary, 20-40% as conjugates); total clearance approximates 1-2 L/day in euthyroid patients.
Renal excretion accounts for 70-80% of clearance, primarily as unchanged drug. Biliary/fecal elimination constitutes 15-20%, with the remainder as minor metabolites.
Category C
Category C
Thyroid Hormone
Thyroid Hormone